Skip to main content
European Commission logo
enen
Public Health

Overview

Vaccination is the main tool for primary prevention of disease and one of the most cost-effective public health measures available.

Immunisation through vaccination is the best defence we have against serious, preventable, and sometimes deadly, contagious diseases.

Thanks to widespread vaccination, smallpox has been eradicated, Europe made polio-free, and many other diseases almost eliminated.

Current challenges

Today, more than 100 million children worldwide are vaccinated annually against diseases such as diphtheria, tetanus, pertussis, tuberculosis, polio, measles, and hepatitis B.

According to the World Health Organization (WHO), vaccination prevents an estimated 2-3 million deaths worldwide each year and reduces disease-specific treatment costs, including antimicrobial treatments (prescribed for viral infections).

Despite its brilliant track record, several EU and neighbouring countries have faced unprecedented outbreaks of vaccine-preventable diseases due to insufficient vaccination coverage rates.

The waning of public confidence in vaccination, geographical differences in accessibility, and rise of mis- and disinformation on vaccination are a cause of concern and a major challenge for public health experts.

Ensuring equitable access to vaccines for all EU citizens, fighting mis- and disinformation, and improving vaccine confidence are objectives shared by the European Commission and EU Member States.

There are very strict rules within the European Union for the approval of any vaccines put on the market.

The European Medicines Agency (EMA) carries out the evaluation and supervision of vaccines, once these have been designed. Following very comprehensive testing, the European Commission can then issue a marketing authorisation.

Once on the market, EMA continues to evaluate the safety of the vaccines and performs post-authorisation surveillance. All these steps are devised to ensure maximum safety, with the ultimate concern being the health and wellbeing of the population.

All components of vaccines marketed in the European Union undergo intense scrutiny and have been, through various studies, deemed safe in the context of those vaccines.

Action at EU level

Vaccination policy is a competence of national authorities, but the European Commission supports EU countries in coordinating their policies and programmes.

In December 2018, EU Health Ministers adopted a Council Recommendation on strengthened cooperation against vaccine-preventable diseases. 

Actions called for by this policy initiative aim for example to coordinate vaccine procurement, support research and innovation and tackle vaccine hesitancy, the overall objective being to increase the uptake of vaccination in the EU in a life-course perspective.

In addition the Commission supports EU countries in maintaining or increasing rates of vaccination by:

One of the goals of Europe's Beating Cancer Plan is to eliminate cervical cancer by vaccinating young people against the Human papillomavirus (HPV) that causes it and is also linked to head and neck, and anal cancers.

Specifically, the Plan calls for vaccinating at least 90% of the EU's target population of girls and for significantly increasing the vaccination rate among boys.

In 2024, the Commission presented a proposal for a Council Recommendation on vaccine-preventable cancers to support EU countries in boosting the uptake of vaccination against Human Papillomaviruses (HPV) and Hepatitis B virus (HBV). 

Recommendations to EU countries will include facilitating access to vaccination, targeted communication on the importance of HPV and HBV vaccination in a cancer prevention perspective and better monitoring of vaccination coverage rates to inform public health action.

Safe COVID-19 vaccines for Europeans

Joint Action on Vaccination

The European Commission is reinforcing its support to national vaccination efforts to increase coverage, including through the Joint Action on Vaccination co-funded by the EU Health Programme (€3.55 million).

Launched in 2018, the Joint Action on Vaccination addresses vaccine hesitancy and seeks to increase vaccination coverage in the EU. It is coordinated by INSERM (France) and involves 20 partners (among them 17 EU countries and 3 non-EU countries).

It also works towards strengthening cooperation of national immunisation advisory groups (NITAGs) with a view to increasing transparency and trust in the decision-making process regarding the introduction of new vaccines.

Coalition for Vaccination

A Coalition for Vaccination was established in spring 2019 and brings together European health professionals' and students' associations to advocate for vaccination in their work with citizens and peers. Members of the Coalition for Vaccination commit to delivering accurate information to the public, to fighting myths around vaccination and vaccines, and to exchanging best practices.

It is currently co-chaired by three major European health professionals' associations:

The Coalition published a manifesto on 9 February 2021 with three key reasons why all healthcare professionals should get vaccinated against COVID19 when they get the opportunity.

They also issued a statement in 2021 to support of the annual Flu Awareness campaign, recommending that healthcare professionals get vaccinated against influenza, and a statement in 2022 underlining the importance of routine and childhood vaccination.

The Coalition for Vaccination meets annually to discuss their activities to promote vaccination.

Related information